You are here

Press Release Archive

- Pfizer and Ranbaxy Settle Lipitor Patent Litigation Worldwide

(BUSINESS WIRE)--Pfizer Inc announced today that it has entered into an agreement with generics manufacturer Ranbaxy Laboratories Ltd. of India and certain of its affiliates to settle substantially all their patent litigation worldwide involving Lipitor, the world’s most-prescribed cholesterol-lowering medicine. Under the terms of the agreement, Ranbaxy will have a license to sell generic versions of Lipitor and Caduet in the United

- Pfizer Celebrates 5 Years of High-Impact Corporate Volunteer MissionsPfizer Celebrates 5 Years of High-Impact Corporate Volunteer Missions

(BUSINESS WIRE)--This summer, Maria Machado, a supply chain expert from Brazil, will make an extended visit to Africa – unlike any trip she’s taken before. Maria and 15 of her colleagues at Pfizer, Inc. are part of a now 5-year-old skills-based corporate volunteerism program, the Pfizer Global Health Fellows. Machado works in Pfizer’s Global Manufacturing Division, ensuring medicines reach their final destination

- Pfizer Inc. and the University of Pennsylvania Announce $15 Million Partnership

(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that it has entered into a $15-million dollar collaboration with the University of Pennsylvania School of Medicine. The partnership will include collaborations between Pfizer and the University in the areas of scientific research, clinical development and clinical care and policy. Under the terms of the agreement, Pfizer will pay Penn $15 million over a three-year period, during

- Pfizer and UCSF Form Alliance to Advance a Broad Range of Research

(BUSINESS WIRE)--In a novel experiment to advance new drug discovery and development, as well as stimulate basic research, Pfizer, Inc. and UCSF have launched a collaboration that spans many disciplines, several UC campuses and multiple Pfizer research units. The three year agreement, with research and other support up to $9.5 million, establishes a university team to help identify promising areas of mutual interest and facilitate

- Pfizer Completes Acquisition of Encysive Pharmaceuticals Inc.

(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced that it has completed the acquisition of all remaining outstanding shares of common stock of Encysive Pharmaceuticals Inc. (NASDAQ:ENCY) through a merger of Pfizer’s wholly-owned subsidiary, Explorer Acquisition Corp., with and into Encysive. Encysive is now a wholly-owned subsidiary of Pfizer. In the merger, each share of Encysive’s outstanding common stock was

- Charles E. Triano Joins Pfizer as Head of Investor Relations

(BUSINESS WIRE)--Pfizer Inc today announced that Charles E. Triano will join the company as Senior Vice President, Investor Relations, effective June 23. Mr. Triano, who will be responsible for all investor relations functions, including communicating the financial and operational performance of the company with institutional and retail investors, will report directly to Chief Financial Officer Frank D’Amelio. Since 2000

- Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Martin Mackay, President, Pfizer Global Research & Development, at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference on Wednesday, June 11th at 10:40 a.m. Pacific Daylight Saving Time. To view and listen to the webcast, visit our web site homepage at and click on the

- Pfizer Reviews Progress of Oncology Pipeline and New Commercial Business Unit Structure with Analysts

(BUSINESS WIRE)--Pfizer Inc announced today as part of its commitment to oncology that it expects to start a total of seven Phase 3 studies in 2008; two are open and enrolling, and five are planned to begin by the end of 2008. These trials involve three different compounds: Sutent, axitinib and CP-751,871, and will focus on 4 types of cancers – hepatocelluar (HCC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and

- New Pfizer Data Presented on CP-751,871 across Non-Small Cell Lung Cancer and Ewing's Sarcoma

(BUSINESS WIRE)--Pfizer announced today results from several clinical trials further describing the activity of its investigational compound CP-751,871 in non-small cell lung cancer (NSCLC) and Ewing’s Sarcoma, both diseases with high unmet medical need. The three oral presentations and one poster discussion underscore that the insulin-like growth factor receptor (IGF-1R) is increasingly recognized by the medical community as a relevant

- Updated CDX-110 Data in Glioblastoma Multiforme Presented at 44th Annual ASCO Annual Meeting

(BUSINESS WIRE)--AVANT Immunotherapeutics (Nasdaq: AVAN) and Pfizer, Inc. (NYSE: PFE) today announced the presentation of new data from two Phase 2 studies at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) for CDX-110, an investigational immunotherapeutic vaccine that targets the tumor-specific molecule epidermal growth factor receptor variant III (EGFRvIII). CDX-110 was generally well-tolerated with primary

- Pfizer Oncology ASCO 2008 Media Briefing to Discuss Study Results in Broad Range of Cancers

(BUSINESS WIRE)-- WHAT: Pfizer Oncology will host a journalist briefing at the American Society of Clinical Oncology (ASCO) Annual Meeting on Sunday, June 1, 2008, highlighting key data presentations from a variety of

- Pfizer Names Amy W. Schulman as Senior Vice President and General Counsel

(BUSINESS WIRE)--Pfizer Inc today named Amy W. Schulman as Senior Vice President and General Counsel, effective June 23. In her new role, Ms. Schulman will be responsible for leading Pfizer’s legal division. She will serve on the company’s Executive Leadership Team (ELT) and will report directly to Chairman and Chief Executive Officer Jeffrey B. Kindler. Ms. Schulman joins Pfizer from DLA Piper, where she was a partner

- Australian Full Federal Court Upholds Basic Lipitor Patent, Preventing Launch of Generic Ranbaxy Product

(BUSINESS WIRE)--Pfizer Inc said today that the Australian Full Federal Court in Victoria has upheld on appeal the exclusivity of its basic patent covering atorvastatin, the active ingredient in Lipitor. The ruling, the culmination of a lawsuit filed in 2005 by generic drug manufacturer Ranbaxy, preserves Lipitor’s patent coverage in Australia through May 2012. Ranbaxy can appeal the decision. The court found that a proposed

- Pfizer Invites Public to View and Listen to Webcast of June 2 Pfizer Analyst and Investor Meeting at ASCO

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a meeting with investment analysts and institutional investors to be held on Monday, June 2, at 6:00 p.m. Central Daylight Saving Time, in connection with the annual meeting of the American Society of Clinical Oncology (ASCO). The analyst and investor meeting will include presentations by Pfizer’s oncology leadership team

- New Analysis Showed That High Dose Lipitor Can Reduce the Risk of Cardiovascular Events in Bypass Surgery Patients

(BUSINESS WIRE)--Pfizer Inc announced today that Lipitor® (atorvastatin calcium) 80 mg significantly reduced the risk of major cardiovascular events, including heart attack and stroke, by 27 percent in patients with heart disease who had previous coronary bypass surgery compared with patients taking the 10 mg dose of Lipitor. This analysis, designed and completed following the closure of the five-year Treating to New Targets (TNT) study

- FivePrime and Pfizer Enter Oncology and Diabetes Collaboration

(BUSINESS WIRE)--Five Prime Therapeutics, Inc. and Pfizer Inc. (NYSE:PFE) today announced the initiation of a worldwide collaborative research and license agreement. The collaboration will focus on the discovery of antibody targets and novel therapeutic protein products to treat certain areas of cancer and diabetes. Under the collaboration, FivePrime will screen its comprehensive protein library in both cell-based assays and primary in

- New Pfizer Data in Lung Cancer, Ewing's Sarcoma, Prostate Cancer and Other Difficult-to-Treat Tumor Types to Be Presented at ASCO

(BUSINESS WIRE)--Pfizer announced today that study results across several difficult-to-treat cancers will be presented at the 44th American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3, 2008. Pfizer will hold two briefings for journalists on June 1 and investors on June 2. Researchers will present the latest data from the breadth of Pfizer’s oncology portfolio, focused in four areas of

- Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Pfizer Inc Chief Financial Officer, Frank D’Amelio, at the Citigroup Healthcare Conference on Wednesday, May 21st, at 3:30pm Eastern Daylight Saving Time. To view and listen to the webcast, visit our web site homepage at and click on the “Citigroup Healthcare Conference”

- Pfizer Names Garry Nicholson to Head New Oncology Business Unit

(BUSINESS WIRE)--Pfizer Inc today named Garry A. Nicholson as Senior Vice President, General Manager of the company’s newly created Oncology Business Unit, reporting to Ian Read, President of Pfizer Worldwide Pharmaceutical Operations. Nicholson will serve as head of Pfizer's oncology franchise, with direct responsibility for clinical development, medical affairs, commercial development, sales and marketing. “Garry


Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.


Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.


If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.